Gilead Reports Robust Third-quarter Earnings, Raises 2015 Outlook Again

Gilead Sciences Inc. late Tuesday reported its third-quarter earnings jumped to $4.6 billion, or $3.06 a share, from $2.73 billion, or $1.67 a share, a year earlier. On an adjusted basis, the biotech giant earned $3.22 a share, ahead of $2.87 a share projected by analysts in a FactSet survey. Revenue grew to $8.3 billion from $6.04 billion. Analysts had forecast revenue of $7.8 billion. The company also raised its full-year 2015 revenue outlook to a range of $30 billion to $31 billion versus $29 billion to $30 billion announced in July, the third upward revision this year. Gilead shares fell 1.8% in after-hours trade.